Printer Friendly
The Free Library
14,634,800 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioSyntech Begins Negotiations on a Distribution Agreement for Cartilage Repair Product, BST-CarGel.


Business Editors/Health/Medical Writers

LAVAL, Quebec--(BUSINESS WIRE)--March 4, 2003

BIOSYNTECH (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:BSYI), announced today the signing of an agreement that initiates a 90-day exclusive negotiation period for the marketing, distribution and sales of BioSyntech's cartilage repair product, BST-CarGel(R), in Europe, Australia and New Zealand, by a multi-national orthopedic company.

BST-CarGel(R) is a novel cartilage repair product based on BioSyntech's thermo-sensitive, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. , muco-adhesive and biodegradable BST-Gel(R) formulation. Delivered arthroscopically, BST-CarGel(R) effectively fills cartilage defects and has demonstrated reproducible cartilage regeneration in multiple animal trials. Some studies during the development of this product were completed in collaboration with the Canadian Arthritis Network of Centres of Excellence.

"BioSyntech is excited to be in such negotiations with a solid partner and orthopedic leader, which will ensure a promising future for our novel cartilage repair product", said Amine amine (əmēn`, ăm`ēn): see under amino group.
amine

Any of a class of nitrogen-containing organic compounds derived, either in principle or in practice, from ammonia (NH3).
 Selmani, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Biosyntech, "and we look forward to rapidly reaching a suitable agreement based on established terms and responsibilities."

Biosyntech is also engaged in similar discussions with multiple international companies for distribution agreements which encompass North America and Asia. About BioSyntech

BioSyntech Inc. is an ISO (1) See ISO speed.

(2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI.
 9001:2000 certified, advanced biomaterials company specializing in tissue repair and in the delivery of therapeutic products. The Company's patented platform technology BST-Gel(R), is a multifunctional injectable thermo-sensitive and self-forming hydrogel hy·dro·gel
n.
A colloidal gel in which the particles are dispersed in water.



hydrogel

a gel that contains water.

hydrogel Wound care A polymer absorptive wound dressing. See Dressing.
 that can be used for tissue repair or for targeted delivery of therapeutic agents. These biomaterials are biocompatible, biodegradable, muco-adhesive and provide significant advantages in specialized medical fields including, Tissue Engineering Orthopedics, Reconstructive Surgery Oncology, Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc.

rheu·ma·tol·o·gy
n.
, Vaccines and many other therapeutic areas. For additional information, visit www.biosyntech.com.

THIS PRESS RELEASE CONTAINS CERTAIN "FORWARD-LOOKING" STATEMENTS, AS DEFINED IN THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  OF 1995 THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES. THERE CAN BE NO ASSURANCE THAT SUCH STATEMENTS WILL PROVE TO BE ACCURATE AND THE ACTUAL RESULTS AND FUTURE EVENTS COULD DIFFER MATERIALLY FROM MANAGEMENT'S CURRENT EXPECTATIONS. SUCH FACTORS ARE DETAILED FROM TIME TO TIME IN THE COMPANY'S FILINGS WITH THE REGULATORY AUTHORITIES HAVING JURISDICTION.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 4, 2003
Words:353
Previous Article:E&S Digistar 3 Takes Boeing CyberDome to the Leading Edge of Technology.
Next Article:Kemper's 2002 Results Deteriorate.



Related Articles
BIOSYNTECH/BIOMET TO DEVELOP NEW HARD TISSUE HEALING.(Brief Article)
BIOSYNTECH REPORTS SUCCESSFUL SAFETY EVALUATION OF BST-GEL.
BST SOFTWARE AND PROJECT INCENTIVES ENTER SOLUTION IN THE MICROSOFT PROJECT 2002 BUSINESS VALUE CHALLENGE.
New gel could lead to cartilage repair. (Material Science).(Brief Article)
Cartilage knife.(Product Marketplace)
Ten years ago.(This Month In Agri Marketing)(Brief Article)
NASA enlists Behavioral Science Technology, Inc. to lead agency-wide culture change.
Articular cartilage injuries in the athlete's knee: current concepts in diagnosis and treatment.(Featured CME Topic: Sports Medicine)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles